

Human Papilloma Virus Circulating Cell-Free DNA Kinetics in Cervical Cancer Patients Undergoing Definitive Chemoradiation

Aaron Seo,¹ Weihong Xiao,² Olsi Gjyshi,¹ Kyoko Yoshida-Court,¹ Peng Wei,³ David Swanson,³ Tatiana Cisneros Napravnik,¹ Adam Grippin,¹ Aradhana M Venkatesan,⁴ Megan C Jacobsen,⁵ David T Fuentes,⁵ Erica Lynn,¹ Julie Sammouri,¹ Anuja Jhingran,¹ Melissa Joyner,¹ Lilie L Lin¹, Lauren E Colbert,¹ Maura L Gillison,² Ann H Klopp^{1*}

1 Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX

2 Department of Thoracic-Head & Neck Med Onc, University of Texas MD Anderson Cancer Center, Houston, TX

3 Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, TX


4 Department of Abdominal Imaging, Division of Diagnostic Imaging, University of Texas MD Anderson Cancer Center, Houston, TX

5 Department of Imaging Physics, University of Texas MD Anderson Cancer Center, Houston, TX



First Author: Aaron Seo (aseo@mdanderson.org)

*Corresponding Author: Ann Klopp (aklopp@mdanderson.org)


Supplementary Figures and Tables



Supplementary Figure 1. Individual timecourse plots of ctDNA levels before, during, and after chemORT. Red indicates patients who had an eventual recurrence.

A**B**

Supplementary Figure 2. Percent clearance of HPV cfDNA of all HPV types (A) overall and (B) by cohort.



Supplementary Figure 3. Kaplan-Meier Analysis of Recurrence-Free Survival by Baseline ctDNA status. The logrank test p-value is reported.

Variable	Univariable		Multivariable	
	HR (95% CI, p-value)	C-index	HR (95% CI, p-value)	C-index
Follow-up ctDNA (log10-transformed)	7.21 (1.79-29.0, p=0.0054)	0.828 ± 0.116	9.54 (0.920-99.0, p=0.0588)	0.881 ± 0.098
MRI GTV treatment response	0.240 (0.00505-11.4, p=0.468)	0.601 ± 0.09	0.0104 (1.81x10 ⁻⁹ -60016, p=0.566)	

Supplementary Table 2. Univariable and Multivariable Cox Regression Analyses and C-indices for Recurrence-free Survival.